ADRB3 and hydrops fetalis: While the BEAT HF trials test the beneficial effects of a chronic β3-AR activation in advanced HF, no trial has yet tested the reverse hypothesis—i.e., that a β3-AR antagonist, administered acutely, may improve LV function by antagonizing the negative inotropic effect of β3-AR at the early phase of acute HF (see Section 3 above).